VRTX Long Put Strategy
VRTX (Vertex Pharmaceuticals Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX (Vertex Pharmaceuticals Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $114.99B, a trailing P/E of 26.54, a beta of 0.30 versus the broader market, a 52-week range of 362.5-507.92, average daily share volume of 1.3M, a public-listing history dating back to 1991, approximately 6K full-time employees. These structural characteristics shape how VRTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.30 indicates VRTX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on VRTX?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current VRTX snapshot
As of May 15, 2026, spot at $436.98, ATM IV 27.56%, IV rank 26.31%, expected move 7.90%. The long put on VRTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long put structure on VRTX specifically: VRTX IV at 27.56% is on the cheap side of its 1-year range, which favors premium-buying structures like a VRTX long put, with a market-implied 1-standard-deviation move of approximately 7.90% (roughly $34.53 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VRTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on VRTX should anchor to the underlying notional of $436.98 per share and to the trader's directional view on VRTX stock.
VRTX long put setup
The VRTX long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VRTX near $436.98, the first option leg uses a $435.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VRTX chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VRTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $435.00 | $12.95 |
VRTX long put risk and reward
- Net Premium / Debit
- -$1,295.00
- Max Profit (per contract)
- $42,204.00
- Max Loss (per contract)
- -$1,295.00
- Breakeven(s)
- $422.05
- Risk / Reward Ratio
- 32.590
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
VRTX long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on VRTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$42,204.00 |
| $96.63 | -77.9% | +$32,542.24 |
| $193.25 | -55.8% | +$22,880.48 |
| $289.86 | -33.7% | +$13,218.72 |
| $386.48 | -11.6% | +$3,556.96 |
| $483.10 | +10.6% | -$1,295.00 |
| $579.72 | +32.7% | -$1,295.00 |
| $676.33 | +54.8% | -$1,295.00 |
| $772.95 | +76.9% | -$1,295.00 |
| $869.57 | +99.0% | -$1,295.00 |
When traders use long put on VRTX
Long puts on VRTX hedge an existing long VRTX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying VRTX exposure being hedged.
VRTX thesis for this long put
The market-implied 1-standard-deviation range for VRTX extends from approximately $402.45 on the downside to $471.51 on the upside. A VRTX long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long VRTX position with one put per 100 shares held. Current VRTX IV rank near 26.31% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on VRTX at 27.56%. As a Healthcare name, VRTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VRTX-specific events.
VRTX long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VRTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VRTX alongside the broader basket even when VRTX-specific fundamentals are unchanged. Long-premium structures like a long put on VRTX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current VRTX chain quotes before placing a trade.
Frequently asked questions
- What is a long put on VRTX?
- A long put on VRTX is the long put strategy applied to VRTX (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With VRTX stock trading near $436.98, the strikes shown on this page are snapped to the nearest listed VRTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are VRTX long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the VRTX long put priced from the end-of-day chain at a 30-day expiry (ATM IV 27.56%), the computed maximum profit is $42,204.00 per contract and the computed maximum loss is -$1,295.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a VRTX long put?
- The breakeven for the VRTX long put priced on this page is roughly $422.05 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VRTX market-implied 1-standard-deviation expected move is approximately 7.90%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on VRTX?
- Long puts on VRTX hedge an existing long VRTX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying VRTX exposure being hedged.
- How does current VRTX implied volatility affect this long put?
- VRTX ATM IV is at 27.56% with IV rank near 26.31%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.